University of California San Francisco

Publications

  1. ASO Visual Abstract: Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
    2025 | PubMed
  2. Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC).
    2024 | PubMed
  3. Graft choice in pancreatectomy with vascular resection: equivalent safety in selected patients.
    2024 | PubMed
  4. ASO Visual Abstract: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    2024 | PubMed
  5. Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
    2024 | PubMed
  6. Enucleation of Neuroendocrine Liver Metastases.
    2024 | PubMed
  7. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    2024 | PubMed
  8. ASO Author Reflections: Total Neoadjuvant Therapy with Chemotherapy Alone for Pancreatic Cancer?
    2024 | PubMed
  9. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    2024 | PubMed
  10. ASO Author Reflections: Minimally Invasive Surgery for Prototypical Small Intestinal Neuroendocrine Tumors.
    2024 | PubMed
  11. Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    2024 | PubMed
  12. National practice patterns in the use of endoscopic ultrasound biopsy for resectable Pancreatic Neuroendocrine Tumors: Insights into the role of DOTATATE PET/CT in diagnosis.
    2024 | PubMed
  13. Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors.
    2024 | PubMed
  14. Robotic-assisted endoluminal gastric leiomyoma resection: a novel surgical technique for benign gastroesophageal junction tumors.
    2024 | PubMed
  15. Improved survival of patients receiving immunotherapy and chemotherapy following curative-intent resection of colorectal liver metastases.
    2024 | PubMed
  16. A Machine Learning Approach to Predict Postoperative Pancreatic Fistula After Pancreaticoduodenectomy Using Only Preoperatively Known Data.
    2023 | PubMed
  17. ASO Visual Abstract: National Practice Patterns in Malignant Peritoneal Mesothelioma-Updates in Management and Survival.
    2023 | PubMed
  18. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.
    2023 | PubMed
  19. Residual Tumor Volume, Not Percent Cytoreduction, Matters for Surgery of Neuroendocrine Liver Metastasis.
    2023 | PubMed
  20. Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
    2023 | PubMed
  21. National Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.
    2023 | PubMed
  22. Laparoscopic Gastrectomy for Gastric Cancer.
    2023 | PubMed
  23. Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data.
    2023 | PubMed
  24. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
    2023 | PubMed
  25. Hypertension Requiring Medication Use: a Silent Predictor of Poor Outcomes After Pancreaticoduodenectomy.
    2023 | PubMed
  26. Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States.
    2022 | PubMed
  27. Hand-Assisted Versus Pure Minimally-Invasive Distal Pancreatectomy: Is There a Downside to Lending a Hand?
    2022 | PubMed
  28. Minimally Invasive Distal Pancreatectomy Techniques: A Contemporary Analysis Exploring Trends, Similarities, and Differences to Open Surgery.
    2022 | PubMed
  29. Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors.
    2022 | PubMed
  30. ASO Visual Abstract: Determining Hospital Volume Threshold for the Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis.
    2022 | PubMed
  31. Optimal Staging for Gastric Cancer Starts With High-Resolution Computed Tomography.
    2021 | PubMed
  32. Determining Hospital Volume Threshold for Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis.
    2021 | PubMed
  33. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study.
    2021 | PubMed
  34. Evidence-Based Guidelines for Branch-Duct Intraductal Papillary Mucinous Neoplasm Management: Still a Lot of Room to Grow.
    2021 | PubMed
  35. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms.
    2021 | PubMed
  36. Burden of Ionizing Radiation in the Diagnosis and Management of Necrotizing Pancreatitis.
    2021 | PubMed
  37. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    2021 | PubMed
  38. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.
    2021 | PubMed
  39. Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    2021 | PubMed
  40. Contemporary Management of Hepatic Cyst Disease: Techniques and Outcomes at a Tertiary Hepatobiliary Center.
    2020 | PubMed
  41. Hybrid Low-Grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma of the Pancreas.
    2020 | PubMed
  42. Randomized Clinical Trial of Nasogastric Tube Placement After Pancreaticoduodenectomy.
    2020 | PubMed
  43. Synchronous Versus Metachronous Colorectal Liver Metastasis Yields Similar Survival in Modern Era.
    2020 | PubMed
  44. Awareness of a mesenteric mass as a common manifestation of ileal neuroendocrine tumor.
    2020 | PubMed
  45. Patterns of chromosome 18 loss of heterozygosity in multifocal ileal neuroendocrine tumors.
    2020 | PubMed
  46. Ampullary stenosis and choledocholithiasis post Roux-En-Y gastric bypass: challenges of biliary access and intervention.
    2020 | PubMed
  47. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
    2020 | PubMed
  48. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
    2019 | PubMed
  49. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
    2019 | PubMed
  50. Adjuvant Therapy for Ampullary Cancer.
    2019 | PubMed
  51. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    2019 | PubMed
  52. Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.
    2019 | PubMed
  53. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
    2019 | PubMed
  54. Pancreatic Adenocarcinoma, Version 1.2019.
    2019 | PubMed
  55. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
    2019 | PubMed
  56. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    2018 | PubMed
  57. Outcomes of arterial bypass preceding resection of retroperitoneal masses involving major vessels.
    2018 | PubMed
  58. Progress in the March to Precision Cancer Medicine: Left, Right, Left.
    2018 | PubMed
  59. Challenges Staging Neuroendocrine Tumors of the Pancreas, Jejunum and Ileum, and Appendix.
    2017 | PubMed
  60. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
    2017 | PubMed
  61. Gastrocutaneous Fistula in a Patient with Locally Recurrent MSI-High Colorectal Cancer: Local Complications Arising from Therapeutic Response to Immune Checkpoint Blockade.
    2017 | PubMed
  62. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.
    2017 | PubMed
  63. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.
    2017 | PubMed
  64. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
    2016 | PubMed
  65. Finding the Common Thread in Rare Diseases.
    2016 | PubMed
  66. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging.
    2015 | PubMed
  67. Solid pseudopapillary neoplasm of the pancreas head in a pregnant woman: safe pancreaticoduodenectomy postpartum.
    2015 | PubMed
  68. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
    2015 | PubMed
  69. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer.
    2014 | PubMed
  70. Bone metastases and skeletal-related events from neuroendocrine tumors.
    2014 | PubMed
  71. Neuroendocrine tumors of unknown primary: is the primary site really not known?
    2014 | PubMed
  72. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.
    2014 | PubMed
  73. Time to put another surgical dogma to sleep?
    2014 | PubMed
  74. Home, sweet home, after surgery.
    2014 | PubMed
  75. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    2013 | PubMed
  76. Management of well-differentiated gastrointestinal neuroendocrine tumors metastatic to the liver.
    2013 | PubMed
  77. Reply to P.H. Sugarbaker.
    2013 | PubMed
  78. Can CT features differentiate between inferior vena cava leiomyosarcomas and primary retroperitoneal masses?
    2013 | PubMed
  79. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    2012 | PubMed
  80. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
    2012 | PubMed
  81. Pseudomyxoma peritonei: more questions than answers.
    2012 | PubMed
  82. Complete and safe resection of challenging retroperitoneal tumors: anticipation of multi-organ and major vascular resection and use of adjunct procedures.
    2011 | PubMed
  83. Unique patterns of metastases in common and rare types of malignancy.
    2011 | PubMed
  84. Pancreatic adenocarcinoma.
    2010 | PubMed
  85. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
    2010 | PubMed
  86. Arterial embolization for the management of gastrointestinal hemorrhage from metastatic renal cell carcinoma.
    2010 | PubMed
  87. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
    2010 | PubMed
  88. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.
    2010 | PubMed
  89. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.
    2009 | PubMed
  90. Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.
    2008 | PubMed
  91. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.
    2008 | PubMed
  92. Compound muscle action potentials and spontaneous electromyography can be used to identify and protect the femoral nerve during resection of large retroperitoneal tumors.
    2008 | PubMed
  93. Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas.
    2008 | PubMed
  94. Introduction.
    2007 | PubMed
  95. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.
    2007 | PubMed
  96. Palliative care for patients with advanced pancreatic and biliary cancers.
    2007 | PubMed
  97. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
    2007 | PubMed
  98. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region.
    2007 | PubMed
  99. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.
    2006 | PubMed
  100. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling.
    2005 | PubMed
  101. Notch signaling induces rapid degradation of achaete-scute homolog 1.
    2002 | PubMed
  102. Mammalian Scratch participates in neuronal differentiation in P19 embryonal carcinoma cells.
    2001 | PubMed
  103. Mammalian Scratch: a neural-specific Snail family transcriptional repressor.
    2001 | PubMed
  104. Management of hepatocellular carcinoma.
    2000 | PubMed
  105. Long-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy.
    1996 | PubMed
  106. A non-lymphocyte-depleting monoclonal antibody to the adhesion molecule LFA-1 (CD11a) prevents sensitization to alloantigens and effectively prolongs the survival of heart allografts.
    1993 | PubMed
  107. Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion.
    1993 | PubMed
  108. Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53.
    2024 | PubMed
  109. Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.
    2024 | PubMed
  110. Metastatic insulinoma-outcomes in the current era.
    2024 | PubMed
  111. Withdrawal pain following patients discontinuing Trk inhibitors.
    2024 | PubMed
  112. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
    2024 | PubMed
  113. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.
    2024 | PubMed
  114. Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    2024 | PubMed
  115. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.
    2024 | PubMed
  116. Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.
    2024 | PubMed
  117. The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy.
    2024 | PubMed
  118. Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors.
    2023 | PubMed
  119. The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study.
    2023 | PubMed
  120. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    2023 | PubMed
  121. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
    2023 | PubMed
  122. The Careers and Professional Well-Being of Women Oncologists During the COVID-19 Pandemic: Responding for Tomorrow.
    2023 | PubMed
  123. Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine Tumors.
    2023 | PubMed
  124. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.
    2023 | PubMed
  125. Preclinical Models of Adrenocortical Cancer.
    2023 | PubMed
  126. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
    2023 | PubMed
  127. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
    2023 | PubMed
  128. Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review.
    2023 | PubMed
  129. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis.
    2023 | PubMed
  130. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
    2023 | PubMed
  131. Preclinical Models of Neuroendocrine Neoplasia.
    2022 | PubMed
  132. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
    2022 | PubMed
  133. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
    2022 | PubMed
  134. Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.
    2022 | PubMed
  135. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?
    2022 | PubMed
  136. Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.
    2022 | PubMed
  137. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
    2021 | PubMed
  138. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips.
    2021 | PubMed
  139. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study.
    2021 | PubMed
  140. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
    2021 | PubMed
  141. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    2021 | PubMed
  142. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms.
    2021 | PubMed
  143. The Immunotherapy Landscape in Adrenocortical Cancer.
    2021 | PubMed
  144. Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.
    2021 | PubMed
  145. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.
    2021 | PubMed
  146. Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    2021 | PubMed
  147. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.
    2021 | PubMed
  148. Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis.
    2021 | PubMed
  149. Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms.
    2021 | PubMed
  150. Carcinoid Crisis-Induced Acute Systolic Heart Failure.
    2020 | PubMed
  151. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.
    2020 | PubMed
  152. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors.
    2020 | PubMed
  153. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of
    2020 | PubMed
  154. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19.
    2020 | PubMed
  155. Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?
    2020 | PubMed
  156. Reply to S. Boutayeb et al.
    2020 | PubMed
  157. Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors.
    2020 | PubMed
  158. Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk.
    2020 | PubMed
  159. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
    2020 | PubMed
  160. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
    2020 | PubMed
  161. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.
    2020 | PubMed
  162. A Rare Case of Carcinoid Constrictive Pericarditis.
    2020 | PubMed
  163. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
    2019 | PubMed
  164. Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma.
    2019 | PubMed
  165. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.
    2019 | PubMed
  166. Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome.
    2019 | PubMed
  167. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
    2019 | PubMed
  168. Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors.
    2019 | PubMed
  169. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    2019 | PubMed
  170. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.
    2019 | PubMed
  171. Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.
    2019 | PubMed
  172. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
    2019 | PubMed
  173. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
    2019 | PubMed
  174. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
    2019 | PubMed
  175. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
    2019 | PubMed
  176. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.
    2018 | PubMed
  177. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    2018 | PubMed
  178. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
    2018 | PubMed
  179. Progress in the Evaluation and Treatment of Small Bowel Neuroendocrine Tumors.
    2018 | PubMed
  180. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
    2018 | PubMed
  181. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
    2018 | PubMed
  182. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.
    2017 | PubMed
  183. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.
    2017 | PubMed
  184. Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series.
    2017 | PubMed
  185. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.
    2017 | PubMed
  186. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.
    2017 | PubMed
  187. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases.
    2017 | PubMed
  188. Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.
    2017 | PubMed
  189. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
    2017 | PubMed
  190. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.
    2017 | PubMed
  191. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.
    2016 | PubMed
  192. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
    2016 | PubMed
  193. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
    2016 | PubMed
  194. A phase II study of axitinib in advanced neuroendocrine tumors.
    2016 | PubMed
  195. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
    2016 | PubMed
  196. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
    2016 | PubMed
  197. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.
    2015 | PubMed
  198. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging.
    2015 | PubMed
  199. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
    2015 | PubMed
  200. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.
    2015 | PubMed
  201. Transcatheter pulmonic valve replacement in carcinoid heart disease.
    2015 | PubMed
  202. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.
    2015 | PubMed
  203. Combined mammalian target of rapamycin and vascular endothelial growth factor pathway inhibition in pancreatic neuroendocrine tumors: more than the sum of its parts?
    2015 | PubMed
  204. Is more not better?: combination therapies in colorectal cancer treatment.
    2015 | PubMed
  205. Neuroendocrine tumors, version 1.2015.
    2015 | PubMed
  206. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
    2015 | PubMed
  207. Bone metastases and skeletal-related events from neuroendocrine tumors.
    2014 | PubMed
  208. Neuroendocrine tumors of unknown primary: is the primary site really not known?
    2014 | PubMed
  209. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
    2014 | PubMed
  210. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.
    2014 | PubMed
  211. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.
    2014 | PubMed
  212. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial.
    2014 | PubMed
  213. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
    2013 | PubMed
  214. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    2013 | PubMed
  215. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
    2013 | PubMed
  216. Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors.
    2013 | PubMed
  217. The evolving landscape of neuroendocrine tumors.
    2013 | PubMed
  218. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
    2012 | PubMed
  219. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    2012 | PubMed
  220. Neuroendocrine tumors.
    2012 | PubMed
  221. Systemic therapy for advanced carcinoid tumors: where do we go from here?
    2012 | PubMed
  222. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
    2012 | PubMed
  223. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial.
    2011 | PubMed
  224. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
    2011 | PubMed
  225. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
    2010 | PubMed
  226. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
    2010 | PubMed
  227. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.
    2010 | PubMed
  228. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
    2010 | PubMed
  229. Glycemic control in patients with insulinoma treated with everolimus.
    2009 | PubMed
  230. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.
    2008 | PubMed
  231. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
    2008 | PubMed
  232. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    2008 | PubMed
  233. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    2008 | PubMed
  234. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
    2008 | PubMed
  235. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
    2008 | PubMed
  236. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
    2007 | PubMed
  237. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
    2007 | PubMed
  238. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
    2007 | PubMed
  239. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region.
    2007 | PubMed
  240. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
    2007 | PubMed
  241. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
    2006 | PubMed
  242. Pancreatoblastoma in an adult: case report and review of the literature.
    2006 | PubMed
  243. Targeting growth factors and angiogenesis; using small molecules in malignancy.
    2006 | PubMed
  244. When does the presence of the target predict response to the targeted agent?
    2005 | PubMed
  245. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
    2005 | PubMed
  246. Anti-angiogenic strategies in gastrointestinal malignancies.
    2005 | PubMed
  247. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
    2005 | PubMed
  248. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    2005 | PubMed
  249. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.
    2005 | PubMed
  250. Update on clinical trials targeting vascular endothelial growth factor in cancer.
    2004 | PubMed
  251. Vascular endothelial growth factor as a therapeutic target in cancer.
    2004 | PubMed
  252. Angiogenesis in colorectal cancer: therapeutic implications and future directions.
    2004 | PubMed
  253. Maximizing the potential of bevacizumab in cancer treatment.
    2004 | PubMed
  254. Couples therapy at end of life.
    2003 | PubMed
  255. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
    2003 | PubMed
  256. Immune enhancement of skin carcinogenesis by CD4+ T cells.
    2003 | PubMed
  257. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
    2003 | PubMed
  258. Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature.
    2003 | PubMed
  259. Shedding old paradigms: developing viruses to treat cancer.
    2002 | PubMed
  260. Molecular mechanisms underlying the development of hepatocellular carcinoma.
    2001 | PubMed
  261. Hepatocellular carcinoma.
    2000 | PubMed
  262. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.
    2000 | PubMed
  263. Human acellular dermal matrix as a novel model of malignant epithelial cell invasion.
    1997 | PubMed
  264. Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data.
    2023 | PubMed
  265. STAT3 regulates inflammatory cytokine production downstream of TNFR1 by inducing expression of TNFAIP3/A20.
    2022 | PubMed
  266. Synchronous Versus Metachronous Colorectal Liver Metastasis Yields Similar Survival in Modern Era.
    2020 | PubMed
  267. RBMS1 Suppresses Colon Cancer Metastasis through Targeted Stabilization of Its mRNA Regulon.
    2020 | PubMed
  268. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
    2020 | PubMed
  269. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
    2019 | PubMed
  270. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
    2019 | PubMed
  271. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    2019 | PubMed
  272. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    2019 | PubMed
  273. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
    2019 | PubMed
  274. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
    2019 | PubMed
  275. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    2018 | PubMed
  276. Sampling strategies to capture single-cell heterogeneity.
    2017 | PubMed
  277. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
    2017 | PubMed
  278. Reply to L. Casadaban et al.
    2017 | PubMed
  279. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
    2016 | PubMed
  280. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
    2016 | PubMed
  281. Unexpected insights for anti-EGFR cancer therapy.
    2015 | PubMed
  282. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.
    2015 | PubMed
  283. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
    2014 | PubMed
  284. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    2013 | PubMed
  285. Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress.
    2013 | PubMed
  286. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    2013 | PubMed
  287. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.
    2013 | PubMed
  288. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    2013 | PubMed
  289. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
    2013 | PubMed
  290. Imaging a functional tumorigenic biomarker in the transformed epithelium.
    2012 | PubMed
  291. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    2012 | PubMed
  292. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
    2012 | PubMed
  293. Is there currently an established role for the use of predictive or prognostic molecular markers in the management of colorectal cancer? A point/counterpoint.
    2012 | PubMed
  294. Complete and safe resection of challenging retroperitoneal tumors: anticipation of multi-organ and major vascular resection and use of adjunct procedures.
    2011 | PubMed
  295. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.
    2011 | PubMed
  296. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.
    2011 | PubMed
  297. Pancreatic adenocarcinoma.
    2010 | PubMed
  298. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
    2010 | PubMed
  299. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
    2010 | PubMed
  300. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.
    2010 | PubMed
  301. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.
    2009 | PubMed
  302. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    2009 | PubMed
  303. Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.
    2008 | PubMed
  304. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.
    2008 | PubMed
  305. Association of family history with cancer recurrence and survival among patients with stage III colon cancer.
    2008 | PubMed
  306. Compound muscle action potentials and spontaneous electromyography can be used to identify and protect the femoral nerve during resection of large retroperitoneal tumors.
    2008 | PubMed
  307. Prognostic importance of superior diaphragmatic adenopathy at computed tomography in patients with resectable hepatic metastases from colorectal carcinoma.
    2008 | PubMed
  308. Introduction.
    2007 | PubMed
  309. Palliative care for patients with advanced pancreatic and biliary cancers.
    2007 | PubMed
  310. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2.
    2007 | PubMed
  311. Pancreatoblastoma in an adult: case report and review of the literature.
    2006 | PubMed
  312. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
    2006 | PubMed
  313. Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology.
    2005 | PubMed
  314. [Liver metastases from colorectal cancer. Is the practice of surgery based on the best clinical evidence possible?].
    2005 | PubMed
  315. Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1A in vitro.
    2005 | PubMed
  316. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.
    2005 | PubMed
  317. Liver-directed therapies in colorectal cancer.
    2005 | PubMed
  318. Palliative techniques for hepatic cancer.
    2004 | PubMed
  319. Characterization of triacsin C inhibition of short-, medium-, and long-chain fatty acid: CoA ligases of human liver.
    2004 | PubMed
  320. Aggressive surgery for metastatic liver neuroendocrine tumors.
    2003 | PubMed
  321. beta-Catenin regulates vascular endothelial growth factor expression in colon cancer.
    2003 | PubMed
  322. Distinguishing features of self-limiting adult small-bowel intussusception identified at CT.
    2003 | PubMed
  323. Isolation, sequencing, and expression of a cDNA for the HXM-A form of xenobiotic/medium-chain fatty acid:CoA ligase from human liver mitochondria.
    2003 | PubMed
  324. Thorotrast-induced liver neoplasia: a collective review.
    2002 | PubMed
  325. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis.
    2002 | PubMed
  326. Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond.
    2002 | PubMed
  327. Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells.
    2002 | PubMed
  328. Quantitative fractionation of alkaline phosphatase isoenzymes according to their thermostability.
    1976 | PubMed
  329. Activity and longevity of insect growth regulators against mosquitoes.
    1975 | PubMed
  330. A double-blind controlled therapeutic trial of lorazepam vs medazepam in psychosomatic conditions in general practice.
    1975 | PubMed
  331. Analyses of rumen fluid from "sudden death", lactic acidotic and healthy cattle fed high concentrate ration.
    1975 | PubMed
  332. Action of propranolol on mitochondrial functions--effects on energized ion fluxes in the presence of valinomycin.
    1975 | PubMed
  333. Digitoxin metabolism by rat liver microsomes.
    1975 | PubMed
  334. Reply to: "Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy," "Large-Scale DPD Testing Should Be More Than an Option," and "A Big Problem With a Feasible Solution, Not a Small Problem With a Complex Solution".
    2024 | PubMed
  335. Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma-a real-world, multicenter study.
    2024 | PubMed
  336. Expansion of a bacterial operon during cancer treatment ameliorates drug toxicity.
    2024 | PubMed
  337. Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer.
    2024 | PubMed
  338. Association between gastrointestinal symptoms and specialty care utilization among colon cancer survivors: a cohort study.
    2024 | PubMed
  339. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.
    2024 | PubMed
  340. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
    2024 | PubMed
  341. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
    2024 | PubMed
  342. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).
    2024 | PubMed
  343. DPYD Pharmacogenetics: To Opt-in or to Opt-out.
    2024 | PubMed
  344. q-Diffusion leverages the full dimensionality of gene coexpression in single-cell transcriptomics.
    2024 | PubMed
  345. Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapies.
    2024 | PubMed
  346. HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405.
    2024 | PubMed
  347. CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma.
    2024 | PubMed
  348. Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.
    2024 | PubMed
  349. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
    2024 | PubMed
  350. CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value.
    2024 | PubMed
  351. Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy.
    2023 | PubMed
  352. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).
    2023 | PubMed
  353. DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
    2023 | PubMed
  354. Associations between the Gut Microbiota, Race, and Ethnicity of Patients with Colorectal Cancer: A Pilot and Feasibility Study.
    2023 | PubMed
  355. Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance).
    2023 | PubMed
  356. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database.
    2023 | PubMed
  357. Variety of Fruit and Vegetables and Alcohol Intake are Associated with Gut Microbial Species and Gene Abundance in Colorectal Cancer Survivors.
    2023 | PubMed
  358. Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance).
    2023 | PubMed
  359. Barriers and confidence among colorectal and prostate cancer survivors participating in two behavioral intervention studies.
    2023 | PubMed
  360. Flashback Foreword: IFL/FOLFOX/IROX in Advanced Colorectal Cancer and FOLFIRI and FOLFOX6 in Colorectal Cancer.
    2023 | PubMed
  361. NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.
    2023 | PubMed
  362. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).
    2023 | PubMed
  363. Preoperative Treatment of Locally Advanced Rectal Cancer.
    2023 | PubMed
  364. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
    2023 | PubMed
  365. Neoadjuvant Immunotherapy for Colorectal Cancer: Too Good to Be True?
    2023 | PubMed
  366. Sexual function remains persistently low in women after treatment for colorectal cancer and anal squamous cell carcinoma.
    2023 | PubMed
  367. Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data.
    2023 | PubMed
  368. Quality of life among colorectal cancer survivors participating in a pilot randomized controlled trial of a web-based dietary intervention with text messages.
    2023 | PubMed
  369. Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases.
    2022 | PubMed
  370. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.
    2022 | PubMed
  371. Association between adherence to the American Cancer Society Nutrition and Physical Activity Guidelines and stool frequency among colon cancer survivors: a cohort study.
    2022 | PubMed
  372. Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292).
    2022 | PubMed
  373. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
    2022 | PubMed
  374. Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism.
    2022 | PubMed
  375. ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer.
    2022 | PubMed
  376. Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).
    2022 | PubMed
  377. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
    2022 | PubMed
  378. Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405.
    2022 | PubMed
  379. Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
    2022 | PubMed
  380. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance).
    2022 | PubMed
  381. Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab.
    2022 | PubMed
  382. Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    2022 | PubMed
  383. Colorectal Cancer Surveillance With Circulating Tumor DNA Assay.
    2022 | PubMed
  384. Quality of life of colorectal cancer survivors participating in a pilot randomized controlled trial of physical activity trackers and daily text messages.
    2022 | PubMed
  385. Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer.
    2022 | PubMed
  386. Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.
    2022 | PubMed
  387. Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis.
    2022 | PubMed
  388. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.
    2022 | PubMed
  389. Feasibility and Acceptability of a Physical Activity Tracker and Text Messages to Promote Physical Activity During Chemotherapy for Colorectal Cancer: Pilot Randomized Controlled Trial (Smart Pace II).
    2022 | PubMed
  390. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.
    2021 | PubMed
  391. Being Present 2.0: Online Mindfulness-Based Program for Metastatic Gastrointestinal Cancer Patients and Caregivers.
    2021 | PubMed
  392. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer.
    2021 | PubMed
  393. Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.
    2021 | PubMed
  394. BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.
    2021 | PubMed
  395. Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling.
    2021 | PubMed
  396. Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931).
    2021 | PubMed
  397. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis.
    2021 | PubMed
  398. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
    2021 | PubMed
  399. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    2021 | PubMed
  400. Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance).
    2021 | PubMed
  401. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
    2021 | PubMed
  402. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    2021 | PubMed
  403. Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.
    2020 | PubMed
  404. Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer.
    2020 | PubMed
  405. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
    2020 | PubMed
  406. IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405.
    2020 | PubMed
  407. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
    2020 | PubMed
  408. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
    2020 | PubMed
  409. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020.
    2020 | PubMed
  410. Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients.
    2020 | PubMed
  411. A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.
    2020 | PubMed
  412. Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405.
    2020 | PubMed
  413. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
    2020 | PubMed
  414. Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer.
    2020 | PubMed
  415. Feasibility and Acceptability of a Web-Based Dietary Intervention with Text Messages for Colorectal Cancer: A Randomized Pilot Trial.
    2020 | PubMed
  416. Heated Intraperitoneal Chemotherapy for Colorectal Carcinomatosis: Emerging Evidence.
    2020 | PubMed
  417. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.
    2019 | PubMed
  418. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.
    2019 | PubMed
  419. Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance).
    2019 | PubMed
  420. Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).
    2019 | PubMed
  421. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology.
    2019 | PubMed
  422. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.
    2019 | PubMed
  423. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer.
    2019 | PubMed
  424. Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    2019 | PubMed
  425. Vitamin D Levels in Patients with Colorectal Cancer and Matched Household Members.
    2019 | PubMed
  426. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    2019 | PubMed
  427. Reply to S. Sorscher.
    2019 | PubMed
  428. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
    2019 | PubMed
  429. Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
    2019 | PubMed
  430. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.
    2019 | PubMed
  431. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
    2019 | PubMed
  432. Self-monitoring and reminder text messages to increase physical activity in colorectal cancer survivors (Smart Pace): a pilot randomized controlled trial.
    2019 | PubMed
  433. Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).
    2019 | PubMed
  434. Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance).
    2019 | PubMed
  435. Genetic variation determines VEGF-A plasma levels in cancer patients.
    2018 | PubMed
  436. Of Microbes and Microsatellites.
    2018 | PubMed
  437. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    2018 | PubMed
  438. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
    2018 | PubMed
  439. Being Present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers.
    2018 | PubMed
  440. Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance).
    2018 | PubMed
  441. Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance).
    2018 | PubMed
  442. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
    2018 | PubMed
  443. Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
    2018 | PubMed
  444. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
    2018 | PubMed
  445. Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).
    2018 | PubMed
  446. Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial.
    2018 | PubMed
  447. Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
    2018 | PubMed
  448. Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer.
    2018 | PubMed
  449. Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer.
    2018 | PubMed
  450. Advances in Adjuvant Therapy for Colon Cancer: P value or Practical Value.
    2018 | PubMed
  451. NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
    2018 | PubMed
  452. Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
    2018 | PubMed
  453. Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance).
    2018 | PubMed
  454. The Developing Role of Anti-Epidermal Growth Factor Receptor Agents in the Treatment of Advanced or Metastatic Colorectal Cancer.
    2017 | PubMed
  455. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
    2017 | PubMed
  456. Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance).
    2017 | PubMed
  457. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
    2017 | PubMed
  458. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
    2017 | PubMed
  459. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    2017 | PubMed
  460. Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).
    2017 | PubMed
  461. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.
    2017 | PubMed
  462. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
    2017 | PubMed
  463. Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy.
    2017 | PubMed
  464. Reply to L. Casadaban et al.
    2017 | PubMed
  465. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
    2017 | PubMed
  466. Right-sided vs left-sided colorectal cancer.
    2017 | PubMed
  467. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.
    2016 | PubMed
  468. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.
    2016 | PubMed
  469. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.
    2016 | PubMed
  470. Role of Biologics in Colon Cancer: Still Not Clear.
    2016 | PubMed
  471. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
    2016 | PubMed
  472. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
    2016 | PubMed
  473. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
    2016 | PubMed
  474. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
    2016 | PubMed
  475. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
    2016 | PubMed
  476. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
    2016 | PubMed
  477. Adjuvant Therapy Trials.
    2016 | PubMed
  478. Metastatic Colorectal Cancer: Lessons Learned, Future Possibilities.
    2016 | PubMed
  479. A phase II study of axitinib in advanced neuroendocrine tumors.
    2016 | PubMed
  480. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.
    2016 | PubMed
  481. Gene Expression Profiling of Evening Fatigue in Women Undergoing Chemotherapy for Breast Cancer.
    2016 | PubMed
  482. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
    2016 | PubMed
  483. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
    2016 | PubMed
  484. NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.
    2015 | PubMed
  485. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
    2015 | PubMed
  486. Subgroups of chemotherapy patients with distinct morning and evening fatigue trajectories.
    2015 | PubMed
  487. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
    2015 | PubMed
  488. Trying to Understand Differing Results of FIRE-3 and 80405: Does the First Treatment Matter More Than Others?
    2015 | PubMed
  489. Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
    2015 | PubMed
  490. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
    2015 | PubMed
  491. On the Verge: Immunotherapy for Colorectal Carcinoma.
    2015 | PubMed
  492. Rectal Cancer, Version 2.2015.
    2015 | PubMed
  493. Special Series: Advances in GI Cancer.
    2015 | PubMed
  494. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.
    2015 | PubMed
  495. Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma.
    2015 | PubMed
  496. Bevacizumab vs EGFR antibodies in metastatic colorectal cancer.
    2015 | PubMed
  497. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
    2015 | PubMed
  498. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
    2015 | PubMed
  499. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
    2014 | PubMed
  500. A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
    2014 | PubMed
  501. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
    2014 | PubMed
  502. Bone metastases and skeletal-related events from neuroendocrine tumors.
    2014 | PubMed
  503. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).
    2014 | PubMed
  504. Progression-free survival: helpful biomarker or clinically meaningless end point?
    2014 | PubMed
  505. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.
    2014 | PubMed
  506. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
    2014 | PubMed
  507. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).
    2014 | PubMed
  508. Hepatobiliary cancers, version 2.2014.
    2014 | PubMed
  509. Colon cancer, version 3.2014.
    2014 | PubMed
  510. Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance).
    2014 | PubMed
  511. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.
    2014 | PubMed
  512. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
    2014 | PubMed
  513. International adaptations of NCCN Clinical Practice Guidelines in Oncology.
    2014 | PubMed
  514. Progress against GI cancer during the American Society of Clinical Oncology's first 50 years.
    2014 | PubMed
  515. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.
    2014 | PubMed
  516. Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities.
    2014 | PubMed
  517. Colorectal cancer: all hands on deck.
    2014 | PubMed
  518. A review of hepatocellular carcinoma (HCC) staging systems.
    2013 | PubMed
  519. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
    2013 | PubMed
  520. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
    2013 | PubMed
  521. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance.
    2013 | PubMed
  522. Biomarkers in colon cancer: the chasm between expectations and reality.
    2013 | PubMed
  523. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
    2013 | PubMed
  524. Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines.
    2013 | PubMed
  525. Predictive biomarkers for bevacizumab: are we there yet?
    2013 | PubMed
  526. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
    2013 | PubMed
  527. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
    2013 | PubMed
  528. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.
    2013 | PubMed
  529. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines.
    2013 | PubMed
  530. Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405.
    2013 | PubMed
  531. Biologic agents in the treatment of colorectal cancer: the last decade; the lost decade?
    2013 | PubMed
  532. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.
    2013 | PubMed
  533. Novel therapeutics in hepatocellular carcinoma: how can we make progress?
    2013 | PubMed
  534. Rectal cancer.
    2012 | PubMed
  535. Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
    2012 | PubMed
  536. Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain.
    2012 | PubMed
  537. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
    2012 | PubMed
  538. When progressive disease does not mean treatment failure: reconsidering the criteria for progression.
    2012 | PubMed
  539. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    2012 | PubMed
  540. Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial.
    2012 | PubMed
  541. Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines.
    2012 | PubMed
  542. Metastatic colorectal cancer: a curable disease.
    2012 | PubMed
  543. Predictive biomarkers in advance of a companion drug: ahead of their time?
    2012 | PubMed
  544. Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel.
    2012 | PubMed
  545. Is there currently an established role for the use of predictive or prognostic molecular markers in the management of colorectal cancer? A point/counterpoint.
    2012 | PubMed
  546. Biomarker use in colorectal cancer therapy.
    2011 | PubMed
  547. Colon cancer.
    2011 | PubMed
  548. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.
    2011 | PubMed
  549. Adjuvant treatment of colon cancer: what is next?
    2011 | PubMed
  550. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303).
    2011 | PubMed
  551. Lactic acidosis and colon cancer: oncologic emergency?
    2011 | PubMed
  552. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
    2011 | PubMed
  553. Long-term outcome of early-stage rectal cancer undergoing standard resection and local excision.
    2011 | PubMed
  554. "And what other medications are you taking?".
    2011 | PubMed
  555. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.
    2011 | PubMed
  556. Perineural invasion in pT3N0 rectal cancer: the incidence and its prognostic effect.
    2010 | PubMed
  557. Nonadherence to imatinib during an economic downturn.
    2010 | PubMed
  558. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.
    2010 | PubMed
  559. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation.
    2010 | PubMed
  560. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
    2010 | PubMed
  561. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.
    2010 | PubMed
  562. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
    2010 | PubMed
  563. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
    2010 | PubMed
  564. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
    2010 | PubMed
  565. NCCN clinical practice guidelines in oncology. Anal carcinoma.
    2010 | PubMed
  566. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective.
    2010 | PubMed
  567. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
    2010 | PubMed
  568. NCCN Clinical Practice Guidelines in Oncology: colon cancer.
    2009 | PubMed
  569. NCCN Clinical Practice Guidelines in Oncology: rectal cancer.
    2009 | PubMed
  570. Drug development in advanced colorectal cancer: challenges and opportunities.
    2009 | PubMed
  571. NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
    2009 | PubMed
  572. A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher.
    2009 | PubMed
  573. Design issues in dose-finding Phase I trials for combinations of two agents.
    2009 | PubMed
  574. Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
    2008 | PubMed
  575. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
    2008 | PubMed
  576. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
    2008 | PubMed
  577. NCCN Task Force Report: mTOR inhibition in solid tumors.
    2008 | PubMed
  578. The impact of new data in the treatment of advanced hepatocellular carcinoma.
    2008 | PubMed
  579. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    2008 | PubMed
  580. Responding to the rising incidence of hepatocellular carcinoma with targeted therapy.
    2008 | PubMed
  581. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
    2008 | PubMed
  582. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
    2008 | PubMed
  583. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
    2007 | PubMed
  584. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
    2007 | PubMed
  585. Section I: essentials of ensuring excellence in cancer care.
    2007 | PubMed
  586. Section III: Treatment of Advanced Gastrointestinal Cancers.
    2007 | PubMed
  587. Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology.
    2007 | PubMed
  588. Colon cancer.
    2007 | PubMed
  589. Rectal cancer.
    2007 | PubMed
  590. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    2007 | PubMed
  591. An alternative therapy for patients with hepatic impairment?
    2007 | PubMed
  592. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
    2007 | PubMed
  593. End points in advanced colon cancer clinical trials: a review and proposal.
    2007 | PubMed
  594. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis.
    2007 | PubMed
  595. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
    2007 | PubMed
  596. Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma.
    2007 | PubMed
  597. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
    2007 | PubMed
  598. Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver.
    2007 | PubMed
  599. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement.
    2006 | PubMed
  600. Hepatobiliary cancers. Clinical practice guidelines in oncology.
    2006 | PubMed
  601. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
    2006 | PubMed
  602. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
    2006 | PubMed
  603. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
    2006 | PubMed
  604. Targeted therapy in colorectal cancer.
    2006 | PubMed
  605. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
    2005 | PubMed
  606. Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
    2005 | PubMed
  607. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
    2005 | PubMed
  608. Anal canal cancer clinical practice guidelines in oncology.
    2005 | PubMed
  609. Colon cancer clinical practice guidelines in oncology.
    2005 | PubMed
  610. Rectal cancer clinical practice guidelines in oncology.
    2005 | PubMed
  611. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma.
    2005 | PubMed
  612. Critical evaluation of current treatments in metastatic colorectal cancer.
    2005 | PubMed
  613. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma.
    2005 | PubMed
  614. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.
    2005 | PubMed
  615. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.
    2004 | PubMed
  616. Cetuximab in the treatment of colorectal cancer.
    2004 | PubMed
  617. Regional therapy of liver metastases.
    2004 | PubMed
  618. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    2004 | PubMed
  619. Key research issues in the management of hepatocellular carcinoma.
    2004 | PubMed
  620. Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer.
    2004 | PubMed
  621. Hepatocellular carcinoma: epidemic and treatment.
    2004 | PubMed
  622. Reactivation of hepatitis C virus after chemotherapy for colon cancer.
    2004 | PubMed
  623. Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite--initial experience with four patients.
    2004 | PubMed
  624. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
    2003 | PubMed
  625. Colorectal metastases confined to the liver: a unique opportunity?
    2003 | PubMed
  626. Induction therapy in patients with metastatic colorectal cancer.
    2003 | PubMed
  627. Adjuvant and neoadjuvant therapy for esophageal cancer: a critical reappraisal.
    2003 | PubMed
  628. Testing the water before diving off the cutting edge.
    2003 | PubMed
  629. Shedding old paradigms: developing viruses to treat cancer.
    2002 | PubMed
  630. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.
    2001 | PubMed
  631. Therapeutic approaches to metastasis confined to the liver.
    2001 | PubMed
  632. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.
    2001 | PubMed
  633. Hepatocellular carcinoma.
    2000 | PubMed
  634. NCCN Practice Guidelines for Colorectal Cancer.
    2000 | PubMed
  635. Hepatocellular carcinoma.
    2000 | PubMed
  636. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
    2000 | PubMed
  637. Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer.
    2000 | PubMed
  638. Regional strategies for managing hepatocellular carcinoma.
    2000 | PubMed
  639. Transcatheter embolization for the treatment of misperfusion after hepatic artery chemoinfusion pump implantation.
    1999 | PubMed
  640. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
    1999 | PubMed
  641. Embolization and chemoembolization therapy for neuroendocrine tumors.
    1999 | PubMed
  642. Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction.
    1998 | PubMed
  643. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
    1998 | PubMed
  644. Update on hepatic intra-arterial chemotherapy.
    1997 | PubMed
  645. Can a vitamin prevent hepatocellular carcinoma?
    1997 | PubMed
  646. Intra-abdominal desmoplastic small round-cell tumor: expansion of the pathologic profile.
    1996 | PubMed
  647. Practice guidelines for colorectal cancer.
    1996 | PubMed
  648. Practice guidelines for esophageal cancer.
    1996 | PubMed
  649. Practice guidelines for gastric cancer.
    1996 | PubMed
  650. Practice guidelines for pancreatic cancer.
    1996 | PubMed
  651. Regional chemotherapy approaches for primary and metastatic liver tumors.
    1996 | PubMed
  652. Pulmonary aspergillosis masquerading as progressive post-transplant lymphoma.
    1996 | PubMed
  653. Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization.
    1995 | PubMed
  654. Treatment of hepatocellular carcinoma: too many options?
    1994 | PubMed
  655. Gallium-avid thymic hyperplasia in an adult after chemotherapy for Hodgkin disease.
    1993 | PubMed
  656. Liver transplantation for hepatocellular carcinoma.
    1993 | PubMed
  657. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
    1993 | PubMed
  658. The Sweet syndrome during therapy with granulocyte colony-stimulating factor.
    1992 | PubMed
  659. Hepatic cancers and their response to chemoembolization therapy. Quantitative image-guided 31P magnetic resonance spectroscopy.
    1992 | PubMed
  660. Hepatic intra-arterial methylene blue injection during endoscopy: a method of detecting gastroduodenal misperfusion in patients receiving hepatic intra-arterial chemotherapy via an implanted pump.
    1992 | PubMed
  661. Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer.
    1991 | PubMed
  662. Chemoembolization for hepatocellular carcinoma.
    1990 | PubMed
  663. Activity of coumarin and cimetidine in metastatic renal cell carcinoma.
    1989 | PubMed
  664. Elevated plasma tamoxifen levels in a patient with liver obstruction.
    1989 | PubMed
  665. Regional chemotherapy for colorectal cancer metastatic to the liver.
    1988 | PubMed
  666. Pentoxifylline and aplastic anemia.
    1987 | PubMed
  667. Prophylactic heparin in APL.
    1987 | PubMed
  668. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group.
    1987 | PubMed
  669. Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing.
    1987 | PubMed